SAMPATRILAT

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H40N4O9S
Molecular Weight	584.682
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(=O)(=O)N[C@@H](CCCCN)C(=O)NC[C@H](CC1(CCCC1)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(O)=O)C(O)=O

InChI

InChIKey=LPUDGHQMOAHMMF-JBACZVJFSA-N

InChI=1S/C26H40N4O9S/c1-40(38,39)30-20(6-2-5-13-27)22(32)28-16-18(23(33)34)15-26(11-3-4-12-26)25(37)29-21(24(35)36)14-17-7-9-19(31)10-8-17/h7-10,18,20-21,30-31H,2-6,11-16,27H2,1H3,(H,28,32)(H,29,37)(H,33,34)(H,35,36)/t18-,20-,21-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9535199 | https://adisinsight.springer.com/drugs/800005729 | https://www.ncbi.nlm.nih.gov/pubmed/21853869

Sampatrilat (also known as UK 81252) was developed as a dual inhibitor of both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). This drug was studied for the treatment of hypertension and congestive heart failure.

Approval Year

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

After a 4-week placebo run-in period, 124 patients with a mean blood pressure of 162/102 mm Hg were randomized in a double-blind parallel-group design to 1 of 5 treatments, given once daily for 10 days: 50 mg, 100 mg, or 200 mg sampatrilat

Route of Administration: Oral

Name

Type

Language

SAMPATRILAT

Official Name

English

Sampatrilat [WHO-DD]

Common Name

English

sampatrilat [INN]

Common Name

English

N-((1-((S)-3-((S)-6-AMINO-2-METHANESULFONAMIDOHEXANAMIDO)-2-CARBOXYPROPYL)CYCLOPENTYL)CARBONYL)-L-TYROSINE

Systematic Name

English

UK-81,252

Code

English

L-TYROSINE, N2-(METHYLSULFONYL)-L-LYSYL-1-((2S)-3-AMINO-2-CARBOXYPROPYL)CYCLOPENTANECARBONYL-

Systematic Name

English

SAMPATRILAT [MI]

Common Name

English

UK-81252

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C247